Dendreon Corporation

Aptevo Research and Development LLC

Dendreon Pharmaceuticals LLC

Sateesh Kumar Natarajan

Ofir Moreno

David Duncan

Reiner Laus

Thomas Graddis

Philip Tan

Feng Chen

Peter Robert Baum

Peter Armstrong Thompson

John W Blankenship

Catherine J McMahan

Thomas J Graddis

David F Duncan

The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with CD3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scFvs, Fabs, di-scFvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments. In one embodiment, a multi-specific polypeptide binds both a T-cell receptor complex on T-cells and a tumor antigen to induce target-dependent T-cell cytotoxicity, activation and proliferation.

CD3 binding polypeptides

This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

CD86 antagonist multi-target binding proteins

Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.

Small-molecule modulators of Trp-p8 activity

Compositions and methods for the treatment of disease associated with TRP-P8 expression

Compositions and methods for the treatment of disease associated with Trp-p8 expression

Small-molecule modulators of TRP-P8 activity

Small-molecule modulators of TRP-p8 activity

Growing community of inventors

Redmond, WA, United States of America

Sateesh Kumar Natarajan